TRIM-edicine is a biotechnology company focused on advancing regenerative medicine through the development of innovative protein therapeutics. Their technology platforms are designed to address unmet medical needs, particularly in the areas of chronic diseases, traumatic injuries, and genetic disorders. The company is actively working on several key proteins, including Mitsugumin53 (MG53), which plays a crucial role in cellular membrane repair and has shown promise in mitigating inflammation and promoting healing across multiple organ systems. Additionally, TRIM-edicine is developing Mitsugumin29 (MG29), a protein linked to muscle function and aging, and ATAP, a therapeutic candidate targeting various cancers that has recently progressed to Phase I clinical trials.

The unique proteins developed by TRIM-edicine are engineered to target specific cellular pathways that are disrupted in various disease states. MG53, for instance, is recognized for its ability to initiate membrane repair following cellular damage, while also demonstrating potential in treating conditions related to aging and organ injuries. The company has made significant advancements in the manufacturing of MG53, achieving high purity levels, and is preparing for regulatory submissions to both the US FDA and China's equivalent. Through these innovative approaches, TRIM-edicine aims to provide effective treatments for a range of serious health conditions, including cancer and age-related diseases.

United States

We are a US biotech company focused on restoring cell health and resilience, with profound initial indications for the treatment of cancers and rare diseases, the protection of multiple organ injuries, and the effective reversal of aging.
We are looking for investors, development partners, or licensees. Interested parties please contact us for further information and discussions.

TRIM-edicine

Company Details